Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: "Roberta Ferraldeschi" Clear advanced filters

  • The progression of prostate cancer to castration-resistant prostate cancer (CRPC) poses considerable therapeutic challenges. Johann de Bono and colleagues review the identification of possible drug targets in CRPC, the evolving CRPC therapeutic landscape and what the future of the treatment of the disease may hold.

    • Timothy A. Yap
    • Alan D. Smith
    • Johann S. de Bono
    Reviews
    Nature Reviews Drug Discovery
    Volume: 15, P: 699-718

  • Over 70 years ago, Huggins and Hodges discovered that prostate cancer depends on androgens. Since then, targeting the androgen receptor signaling pathway has remained the backbone of prostate cancer treatment. This Review discusses the past, present and future of androgen receptor targeting therapeutics.

    • Yien Ning Sophia Wong
    • Roberta Ferraldeschi
    • Johann de Bono
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 11, P: 365-376

  • The National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad) includes academia, industry, patient groups and regulatory bodies representatives. In this Consensus Statement, recommendations are provided with the aim of increasing the number of novel drugs being successfully registered in combination with radiotherapy in clinical trials for patients with cancer.

    • Ricky A. Sharma
    • Ruth Plummer
    • Stephen R. Wedge
    ReviewsOpen Access
    Nature Reviews Clinical Oncology
    Volume: 13, P: 627-642

  • The antiandrogen withdrawal syndrome (AAWS) is characterized by tumour regression on treatment discontinuation. Here, the mechanisms of AAWS and the development of treatment resistance are described, and the implications for the development of novel drugs and the challenges associated with redefining the utility of older treatments are discussed.

    • David Lorente
    • Joaquin Mateo
    • Johann S. de Bono
    Reviews
    Nature Reviews Urology
    Volume: 12, P: 37-47